Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Volume: 34, Issue: 15_suppl, Pages: 4111 - 4111
Published: May 20, 2016
Abstract
4111 Background: FOLFIRINOX is considered one of the standard chemotherapy regimens for chemotherapy-naïve pts. with MPC, but carries an unfavorable adverse event (AE) profile, especially in Japanese Phase II study of full dose FOLFIRINOX, the incidence of grade 3 or more neutropenia and febrile neutropenia was 77.8% and 22.2% respectively. Objective: The purpose of this study was to evaluate the efficacy and safety of modified FOLFIRINOX...
Paper Details
Title
Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Published Date
May 20, 2016
Journal
Volume
34
Issue
15_suppl
Pages
4111 - 4111
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History